Vernal Biosciences
Vernal Biosciences is a Vermont-based mRNA CDMO founded in 2021, offering custom synthesis, LNP formulation, GMP manufacturing, and integrated analytical services for biotech and pharma developers of mRNA therapeutics, vaccines, and gene editing applications.
- Company typePrivate
- Founded2021
- HeadquartersBurlington, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Vernal Biosciences does
Vernal Biosciences is a Burlington/Colchester, Vermont-based contract development and manufacturing organization (CDMO) founded in 2021 that specializes in high-purity mRNA and lipid nanoparticle (LNP) production for research, preclinical, and clinical applications. The company serves biotech and pharmaceutical developers of mRNA therapeutics, vaccines, gene editing therapies, and protein replacement treatments, with named engagements including Repair Biotechnologies and Akagera Medicines. Its product portfolio spans catalog research-grade mRNAs (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, large-scale preclinical production (1 mg to 25 grams), LNP formulation, GMP-grade manufacturing, and integrated analytical services covering Master Cell Bank through mRNA-LNP characterization.
The technical platform rests on three differentiators: a proprietary next-generation mRNA capping technology achieving >98% Cap-1 efficiency with low dsRNA contamination (~0.08%); a Quality-by-Design (QbD) framework implemented through QbDVision software that captures process-experiment data for predictive scale-up; and a flexible LNP formulation capability supporting multiple administration routes. The Colchester facility (23,000 sq ft) houses GMP production suites, three Grade B cGMP cleanrooms, and analytical labs, while a 20,000 sq ft Essex, VT GMP plant is under construction to add multi-suite capacity with sterile fill-finish, positioning Vernal as a one-stop shop from sequence design to clinical supply.
The business model combines two revenue streams: professional-services CDMO contracts (custom synthesis, process development, GMP manufacturing, analytical services) sold via direct enterprise field sales and quote-based pricing, and transactional catalog mRNA product sales through an e-commerce storefront with tiered unit pricing ($305-$7,169 per SKU) and free samples. Vernal monetizes the outsourcing pain point of building in-house mRNA manufacturing infrastructure, generating revenue across the full R&D lifecycle while targeting biotech, pharma, and academic research institutions. The company has raised approximately $41M across seed (2021), a $21M round (June 2022), and a $20M round (June 2023) led by Ampersand Capital Partners, Charles River Labs, Dynamk Capital, and Alloy Therapeutics, and operates with 51-100 employees under new CEO Jim Petrilla appointed October 2024.
Vernal Biosciences firmographics
Firmographics- Name
- Vernal Biosciences
- Legal name
- Vernal Biosciences Inc.
- Website
- https://vernal.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Vernal Biosciences is a Vermont-based mRNA CDMO founded in 2021, offering custom synthesis, LNP formulation, GMP manufacturing, and integrated analytical services for biotech and pharma developers of mRNA therapeutics, vaccines, and gene editing applications.
- Ownership category
- akta.pro rank
Vernal Biosciences industry classification
Industry- Product category
- mRNA Contract Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
- akta.pro secondary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Vernal Biosciences is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Vernal Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- CDMO Contract Manufacturing Services: Full-service contract development and manufacturing organization providing end-to-end mRNA and LNP services from custom synthesis through GMP manufacturing, including process development, analytical services, and sterile fill-finish.
- Catalog mRNA Product Sales: Sale of research-use catalog mRNA products including reporter genes (eGFP, mCherry, FLuc), gene editing (Cre), gene replacement (hEPO), and antigen (OVA) mRNAs in various quantities from 100UG to 5MG.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | eGFP mRNA - Reporter Gene mRNA for research applications |
| Unit Pricing | Pay-as-you-go | mCherry mRNA - Reporter Gene mRNA for research applications |
| Unit Pricing | Pay-as-you-go | FLuc mRNA - Firefly Luciferase mRNA for biodistribution studies |
| Unit Pricing | Pay-as-you-go | OVA mRNA - Antigen mRNA for immunology research |
| Other | Multi-year contract | Custom mRNA synthesis services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Vernal Biosciences product offering
Product offeringCore offering
Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end mRNA and lipid nanoparticle (LNP) manufacturing services from research-grade through GMP-grade production. Its portfolio spans ready-to-order catalog mRNA products (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, GMP mRNA and LNP-mRNA manufacturing, LNP formulation, large-scale production from 1 mg to 25 grams, analytical services, and pre-GMP development for biotech and pharma drug developers.
Product overview
Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of mRNA and lipid nanoparticle (LNP) manufacturing services. The portfolio consists of Catalog mRNA Products (eGFP, mCherry, FLuc, Cre, hEPO, OVA mRNA) for research use, Custom mRNA Synthesis for bespoke applications, and GMP mRNA and LNP-mRNA Manufacturing for clinical supply. Supporting services include LNP-Formulated mRNA, mRNA and LNP Analytical Services, mRNA and LNP Large-Scale Production, mRNA Sequence Design, and Pre-GMP mRNA and LNP Development. The platform is unified through a Quality-by-Design approach, enabling seamless technology transfer from research-grade through GMP clinical manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Catalog mRNA Products Ready-to-use catalog mRNA products for research and preclinical applications, including reporter gene mRNAs (eGFP, mCherry, FLuc), gene editing mRNA (Cre), gene replacement mRNA (hEPO), and antigen mRNA (OVA), incorporating modified nucleoside, Cap-1 structure, optimized codons, and poly(A) tail. Sold in tiered quantities from 100UG to 5MG to academic and industrial researchers.
- Custom mRNA Synthesis Bespoke design and manufacturing of high-purity custom mRNA for any protein target or application, including precision nucleases, gene regulatory proteins, epigenetic editors, secreted and intracellular binding proteins, protein replacement, reporter genes, immunomodulatory genes, cell programming, and fusion proteins. Quote-based service for biotech and pharma developers needing tailored mRNA constructs.
- GMP mRNA and LNP-mRNA Manufacturing GMP-compliant manufacturing services for mRNA drug substance and LNP-mRNA drug product, with detailed process characterization, a Quality-by-Design program, and full analytical assay support for clinical supply. Includes sterile fill-finish. Targeted at biotech and pharma clients advancing mRNA drug candidates into clinical trials.
- LNP-Formulated mRNA Scalable lipid nanoparticle (LNP) formulation services for mRNA delivery using various lipid chemistries, including preclinical LNP manufacturing, formulation optimization, and GMP sterile fill-finish for clinical manufacturing. Supports IV, subcutaneous, intramuscular, intraventricular, and intratumoral routes of administration.
- mRNA and LNP Analytical Services Comprehensive analytical testing services measuring critical quality attributes (CQAs) across mRNA and LNP manufacturing, including Master Cell Bank, plasmid, mRNA, and mRNA-LNP material testing for capping efficiency, poly(A) tail length, dsRNA content, encapsulation efficiency, and lipid composition. Now offered as integrated analytical and QC services for plasmid DNA, mRNA, and LNPs.
- mRNA and LNP Large-Scale Production High-purity mRNA and LNP large-scale production for preclinical studies, including dose range finding and toxicology studies, with production scales ranging from 1 mg to 25 grams. Supports biotech and pharma clients running IND-enabling preclinical work.
- Pre-GMP mRNA and LNP Development Pre-GMP development services including process development, GMP-representative manufacturing process, process documentation, quality establishment, and IND submission support. Designed to de-risk and accelerate the transition from preclinical research to GMP clinical manufacturing.
Quantifiable outcome
- >98% Cap-1 capping efficiency ensuring high potency and reduced inflammatory responses
- +3 more outcomes
Companies that use Vernal Biosciences
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Vernal Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vernal Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- REPROCELLcorePartnership to democratize access to mRNA technology around the world. REPROCELL is a trusted leader in life sciences research products and services.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Vernal Biosciences competitors and assessment
Company assessmentDirect peers
- TriLink BioTechnologies (Maravai LifeSciences): TriLink is the most direct comparable: a specialized mRNA and nucleic acid CDMO offering catalog and custom mRNA, GMP manufacturing, and clean cap analogs. Both companies serve mRNA therapeutic and vaccine developers with research-grade through GMP services.
- Aldevron (Danaher): Aldevron is a leading plasmid DNA, mRNA, and protein CDMO serving gene therapy and mRNA developers. Now owned by Danaher, it provides comparable end-to-end nucleic acid manufacturing from research to GMP scales, competing directly for mRNA and LNP clients.
Broad incumbents
- AGC Biologics: AGC Biologics is a global CDMO offering mRNA, cell therapy, and biologics manufacturing services. Larger and broader than Vernal but with overlapping mRNA CDMO capabilities and a larger customer base in pharma and biotech.
- Lonza: Lonza is one of the largest global CDMOs with significant mRNA and LNP manufacturing capacity built out post-COVID. Operates at much greater scale across multiple modalities; competes for the same pharma customers seeking outsourced mRNA production.
- Catalent (Novo Holdings): Catalent is a major pharmaceutical CDMO with biologics, cell therapy, and nucleic acid capabilities including mRNA. Recently acquired by Novo Holdings, it competes with Vernal for outsourced manufacturing relationships with biotech and pharma clients.
- Recipharm (Ettore Biologics): Recipharm is a European-headquartered CDMO with biologics and nucleic acid capabilities. Operates broader service lines than Vernal but overlaps in mRNA-related manufacturing services for biotech and pharma clients.
- Patheon (Thermo Fisher Scientific): Thermo Fisher's Patheon business is a top-tier global pharma CDMO offering drug substance, drug product, and biologics services. While not specialized in mRNA, it serves many of the same biotech customers and competes for outsourcing budgets.
- Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO with expanding mRNA and vaccine manufacturing capabilities. Significantly larger scale and capacity; serves large pharma clients across multiple modalities.
Emerging players
- eTheRNA immunotherapies: eTheRNA is a Belgium-based mRNA therapeutics developer and CDMO with proprietary LNP technology. Smaller and more focused on its own pipeline but competes for mRNA CDMO clients in the European market.
- Eurofins Genomics: Eurofins Genomics offers custom DNA/RNA synthesis and gene synthesis services with growing mRNA capabilities. Comparable to Vernal's catalog and custom mRNA product lines, particularly for research-grade applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Vernal Biosciences social profiles
Digital presenceVernal Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vernal Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Vernal Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vernal Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vernal Biosciences
What does Vernal Biosciences do?
Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end mRNA and lipid nanoparticle (LNP) manufacturing services from research-grade through GMP-grade production. Its portfolio spans ready-to-order catalog mRNA products (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, GMP mRNA and LNP-mRNA manufacturing, LNP formulation, large-scale production from 1 mg to 25 grams, analytical services, and pre-GMP development for biotech and pharma drug developers.
Is Vernal Biosciences a public or private company?
Vernal Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vernal Biosciences founded?
Vernal Biosciences was founded in 2021. It employs 51 to 100 people.
Where is Vernal Biosciences based?
Vernal Biosciences is headquartered in Burlington, United States, in the North America region.
How does Vernal Biosciences make money?
Two revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are catalog mRNA Product Sales.
Who are Vernal Biosciences's main competitors?
Direct peers on record are TriLink BioTechnologies (Maravai LifeSciences) and Aldevron (Danaher). Broad incumbents are AGC Biologics, Lonza, Catalent (Novo Holdings), Recipharm (Ettore Biologics), Patheon (Thermo Fisher Scientific) and Samsung Biologics. Emerging players are eTheRNA immunotherapies and Eurofins Genomics.
Does Vernal Biosciences have an API?
No public API is recorded for Vernal Biosciences.
What industry is Vernal Biosciences in?
Vernal Biosciences's product category is mRNA Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 8731.